LONDON & NEW YORK, February 26, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...
Compass Pathways stated it intends to use the proceeds to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in post-traumatic stress disorder, acceleration of commercial ...
Compass Pathways currently intends to use the proceeds from these warrant exercises, together with its existing cash and cash equivalents, to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results